Tweet: average medicine takes 10–15 years

An X post on May 25 by the user rao33433 said the average medicine takes 10 to 15 years to reach the market, echoing a figure widely used in pharmaceutical industry materials. PhRMA, the industry trade group, says developing one new medicine takes 10 to 15 years on average and costs $2.6 billion, including the cost of failed attempts. The U.S. Food and Drug Administration describes the path as a sequence of discovery, preclinical research, clinical research, regulatory review and post-market safety monitoring. ### Where does the 10-to-15-year figure come from? PhRMA says the 10-to-15-year estimate covers the full arc from early research to an approved medicine. The group says that timeline includes the cost of “many failures,” and adds that only 12% of new molecular entities that enter clinical trials eventually receive FDA approval. The FDA does not put a single number on the total timeline on its overview page, but it lays out the same broad sequence that helps explain why the process stretches across years. (phrma.org) The agency says research begins in the laboratory, moves through animal and other preclinical testing, then into human studies before an FDA review decision. ### What actually happens before a drug ever reaches patients? Discovery work starts in laboratories, where researchers study a disease and look for biological targets such as proteins, RNA or DNA that might be influenced by a medicine, according to PhRMA. The group says scientists then search for a “lead compound,” a promising molecule that could eventually become a treatment. (fda.gov) Preclinical research comes next. The FDA says drugs undergo laboratory and animal testing at that stage to answer basic safety questions before they can move into testing in people. ### Why do so many projects take years and still fail? PhRMA says attrition is built into the model. The group’s summary says only 12% of new molecular entities that enter clinical trials are ultimately approved by the FDA, meaning most candidates fall away after companies have already spent years and money developing them. (phrma.org) That failure rate helps explain why industry estimates fold unsuccessful programs into the cost and timeline of each approved product. (fda.gov) PhRMA’s $2.6 billion figure is presented as an average that includes those dead ends, not just the winning compound that reaches the market. ### How much of the timeline is regulation versus science? (phrma.org) The FDA says the process is not limited to a final approval decision. Its framework includes discovery and development, preclinical research, clinical research, FDA review and post-market safety monitoring after a product is already available to the public. (phrma.org) Clinical research is one of the longest stages because drugs are tested in people to determine whether they are safe and effective, the FDA says. After that, FDA review teams examine the submitted data and decide whether to approve the product. ### Does approval end the process? The FDA says no. (fda.gov) Its drug-development overview includes post-market safety monitoring as a formal step, meaning regulators continue tracking safety after a medicine is sold. For readers trying to place the viral 10-to-15-year claim, the next place to look is the FDA’s drug-development process page and PhRMA’s research-and-development overview, which set out the stages, failure rates and cost figures behind that estimate. (fda.gov) (phrma.org)